Journal of Clinical & Experimental OncologyISSN: 2324-9110

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Ryan Bear Author

bear@gmail.com

Subjects of specialization
Benzimidazoles, Chemotherapeutic-resistant; Covalent , immunochemotherapeutic; Cytotoxic anti-neoplastic potency, Dual combination anti-cancer therapy

Affiliation
College of Veterinary Medicine at Wise Center, Mississippi State University, USA

Biography

Ryan Bear was working at College of Veterinary Medicine at Wise Center, Mississippi State University, USA. He has more than 50 publiactions. His current research work related to immuno therapy.

Publications

Research Article Open Access

Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicty in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma

Author(s):

C.P. Coyne, Toni Jones and Ryan Bear

Gemcitabine is a pyrimidine nucleoside analog that becomes triphosphorylated and competitively inhibits cytidine incorporation into DNA strands. Diphosphorylated gemcitabine irreversibly inhibits ribonucleotide reductase thereby preventing deoxyribonucleotide synthesis. Functioning as a potent chemotherapeutic, gemcitabine decreases neoplastic cell proliferation and induces apoptosis which accounts for its effectiveness in the clinical treatment of several leukemia and carcinoma cell types. A brief plasma half-life due to rapid deamination, chemotherapeutic-resistance and sequelae restrict gemcitabine utility in view more»

DOI: 10.4172/2324-9110.1000109

Abstract HTML PDF

Google Scholars / Researchers Sites

Explore SciTechnol

GET THE APP